Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ondine Biomedical, Inc. ( (GB:OBI) ) has issued an announcement.
Ondine Biomedical Inc. announced that Ridge Meadows Hospital and Chilliwack General Hospital in British Columbia have adopted its Steriwave nasal photodisinfection as a standard pre-surgical procedure to combat antibiotic resistance and reduce surgical site infections (SSIs). This adoption marks a significant step in the fight against healthcare-associated infections, as Steriwave offers a quick, effective, and resistance-free method to eliminate nasal pathogens, thereby improving patient outcomes and reducing hospital readmissions.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology, approved in several countries, and is undergoing clinical trials in the US.
Average Trading Volume: 160,129
Technical Sentiment Signal: Buy
Current Market Cap: £60.94M
For a thorough assessment of OBI stock, go to TipRanks’ Stock Analysis page.